Cu(II)-Elesclomol
Based on 7 publication(s) in Google Scholar
Cu(II)-Elesclomol is a complex formed by Elesclomol (HY-12040) and Cu2+ (copper ions). Cu(II)-Elesclomol is also a weak inhibitor of DNA topoisomerase I. Cu(II)-Elesclomol exerts anticancer effects by inducing oxidative stress and DNA damage through copper chelation. Cu(II)-Elesclomol can inhibit tumor cell proliferation and induce cell cycle arrest and apoptosis. Cu(II)-Elesclomol can be used in the study of cancer.
For research use only. We do not sell to patients.
- Purity: 99.88%
- CAS No.: 1224195-72-5
- Formula: C19H18CuN4O2S2
- Molecular Weight:462.05
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
NF-κB Signaling Compound Library
HY-L014
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Cuproptosis Compound Library
HY-L133
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
Anti-Aging Compound Library Mini
HY-L034M
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Cu(II)-Elesclomol
More- Cell Death Discov. 2026 May 23. [Abstract]
- RSC Adv. 2025 Dec 12;15(57):49643-49651. [Abstract]
- Int J Mol Sci. 2024 Oct 30;25(21):11657. [Abstract]
- Toxicol Appl Pharmacol. 2025 Oct:503:117496. [Abstract]
- Arch Med Sci. 2025 Apr 20.
- Dig Dis Sci. 2026 Feb 9. [Abstract]
- BMC Med Genomics. 2026 May 30. [Abstract]
Customer Validation & Images
-
WB
-
Cell Imaging/Staining
-
Cell Migration/Invasion Assay
-
Flow Cytometry
-
Cell Proliferation/Viability Assay
All Topoisomerase Isoforms
More
Biological Activity
Cu(II)-Elesclomol (0.001-50 μM; 0-80 h) inhibits the growth of K562 cells (IC50: 7.5 nM), and induces apoptosis, G1 phase cell cycle arrest and DNA double-strand breaks[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:K562 cells
-
Concentration:0.1, 1, 10, 100 and 200 nM
-
Incubation Time:0, 20, 40, 60 and 80 h
-
Result:Inhibited the cell viability.
Chemical Information
-
CAS No. 1224195-72-5
-
Appearance Solid
-
Molecular Weight 462.05
-
Formula C19H18CuN4O2S2
-
Color Brown to reddish brown
-
SMILES
CN1[N-](C(C2)=O)[Cu+2]([S]=C3C4=CC=CC=C4)([S]=C1C5=CC=CC=C5)[N-](C2=O)N3C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Cell Death Discov
Cuproptosis causes meiotic metaphase I arrest by disrupting mitochondrial functions in oocytes. [Abstract]2026 May 23. PMID: 42177195 -
RSC Adv
2025 Dec 12;15(57):49643-49651. PMID: 41395191
Cu(II)-Elesclomol purchased from MedChemExpress. Usage Cited in: RSC Adv. 2025 Dec 12;15(57):49643-49651. [Abstract]
Expression of ATP7B under ZnO nanoparticles, ES (Cu(II)-Elesclomol: 10 μM), and ZnO nanoparticles + ES treatment.
Cu(II)-Elesclomol purchased from MedChemExpress. Usage Cited in: RSC Adv. 2025 Dec 12;15(57):49643-49651. [Abstract]
Effects of ES (Cu(II)-Elesclomol: 10 μM) on intracellular ROS levels.
Cu(II)-Elesclomol purchased from MedChemExpress. Usage Cited in: RSC Adv. 2025 Dec 12;15(57):49643-49651. [Abstract]
Effects of ES (Cu(II)-Elesclomol: 10 μM) on tumor cell invasion.
Cu(II)-Elesclomol purchased from MedChemExpress. Usage Cited in: RSC Adv. 2025 Dec 12;15(57):49643-49651. [Abstract]
Flow cytometry was used to analyze the apoptosis of tumor cells treated with ZnO NPs, ZnO@DNAzyme, ES (Cu(II)-Elesclomol: 10 μM), ZnO NPs + ES, ZnO@DE, and ZnO@DE(M).
-
Int J Mol Sci
The Role of Heat Shock Factor 1 in Preserving Proteomic Integrity During Copper-Induced Cellular Toxicity. [Abstract]2024 Oct 30;25(21):11657. PMID: 39519208 -
Toxicol Appl Pharmacol
2025 Oct:503:117496. PMID: 40749953
Cu(II)-Elesclomol purchased from MedChemExpress. Usage Cited in: Toxicol Appl Pharmacol. 2025 Oct:503:117496. [Abstract]
Effects of copper ion carrier ES-Cu (Cu(II)-Elesclomol) on cell viability.
-
-
Dig Dis Sci
SERPINE1-Driven MAPK Activation Enhances Cuproptosis Resistance and Angiogenic Potential in Colorectal Cancer. [Abstract]2026 Feb 9. PMID: 41661494 -
BMC Med Genomics
Integrative single-cell and bulk transcriptomics define cell death patterns and ZDHHC22 in gastric cancer progression. [Abstract]2026 May 30. PMID: 42218517
Solvent & Solubility
DMSO : 6.67 mg/mL (14.44 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 0.67 mg/mL (1.45 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 0.67 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (6.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Brian B Hasinoff, et al. Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II). hem Pharmacol. 2015 Feb 1;93(3):266-76. [Content Brief]
[2]. Hasinoff BB, et al. The cytotoxicity of the anticancer drug elesclomol is due to oxidative stress indirectly mediated through its complex with Cu(II). J Inorg Biochem. 2014 Aug;137:22-30. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1643 mL | 10.8213 mL | 21.6427 mL | 54.1067 mL |
| 5 mM | 0.4329 mL | 2.1643 mL | 4.3285 mL | 10.8213 mL | |
| 10 mM | 0.2164 mL | 1.0821 mL | 2.1643 mL | 5.4107 mL |
Cu(II)-Elesclomol Related Classifications
HY-156376 Related Classifications
Powered by Bioz